
AbbVie acquires in vivo CAR-T technology with Capstan purchase
AbbVie has revealed it will acquire Capstan Therapeutics, a clinical-stage biotechnology company dedicated to advancing in vivo engineering of cells through RNA delivery using tLNPs. The acquisition will include CPTX2309, a potential first-in-class in vivo tLNP anti-CD19 CAR-T therapy candidate, currently in Phase I development for the treatment of B… Read More
